Diquafosol is a P2Y2 receptor agonist whose mechanism is to improve the symptoms of dry eye disease by promoting water and mucin secretion, bringing the tear film closer to normal.
Diquafosol has good efficacy and tolerance for various types of dry eye, and no serious adverse reactions have been observed, and it has been included in the "Chinese Dry Eye Expert Consensus: Treatment (2020)".
Diquafosol eyedrop can be indicated for all types of dry eye (including mild, moderate, and severe dry eye) except for abnormal tear dynamics. Diquafosol eyedrop is the first-line treatment for water-deficient dry eye.
BFS manufacturing technology, more safe and convenient
BFS high-end production line has higher efficiency and precision, and low overall cost. And disposable packaging has the advantages of effectively reducing cross-contamination, economical use, safety, and easy portability, which can greatly optimize the patient's sense of use.
Strong cost advantage, ample margins
With the strong API cost advantage, the BFS dosage form itself enjoys a sufficient market premium, and the Group ensures that diquafosol eyedrop has sufficient margins.
Good synergy
can form a good synergy effect with other products of the Group in the field of ophthalmology.
Dry eye is one of the most common ocular surface diseases in clinical practice, which can be accompanied by symptoms such as ocular tissue damage due to the decrease in tear film stability and the imbalance of the ocular surface environment. Surveys show that the incidence of dry eye in China is as high as 21.0% to 30.0%, and there are about 360 million dry eye patients in China.
Among the drugs clinically used for the treatment of dry eye in China, artificial tears (mainly sodium hyaluronate eye drops) account for the largest proportion, which can relieve patients with mild dry eye, but cannot fundamentally treat moderate to severe dry eye. The diquafosol dry eye drug is in “Blue Ocean”, and the market has massive expansion potential.
According to CIC, it is estimated that by 2030, the size of China's dry eye drug market will increase significantly at a compound annual growth rate of 28.4% to over 42 billion RMB, and in the next 10 years, dry eye will account for more than 30% of the domestic ophthalmology segment indication market, ranking first.
